CJC 1295 with DAC vs Without DAC and Which One You Should Actually Use
Most people choose CJC 1295 with DAC because fewer injections sounds like the same drug with less inconvenience. It is not. The two versions work through completely different mechanisms, and one of them routes you around the very thing that makes a secretagogue worth using in the first place.
To understand why, you need the full picture of how growth hormone actually works in the body before zooming into what each version does to that system.
Your pituitary releases growth hormone in pulses, not as a steady stream. A peptide called GHRH, which is growth hormone releasing hormone, travels from your hypothalamus to your pituitary and triggers a burst. Then it clears. Then the next pulse fires. Throughout the day you get somewhere between eight and twelve of these pulses, with the largest ones coming during deep sleep, and between each burst the level drops back down to near zero. Those valleys matter as much as the peaks. The rhythm itself, the rise and the fall and the silence between them, is what drives downstream effects like fat breakdown.
CJC 1295 without DAC is built to work inside that rhythm. It is a GHRH analog, meaning it mimics the signal your hypothalamus would naturally send. Its half life is around 30 minutes, so you inject it, it triggers a pulse from your pituitary, and then it clears before the next natural pulse is supposed to fire. Your rhythm stays intact. The secretagogue amplifies the system without rewriting it.
DAC changes the equation entirely.
DAC stands for drug affinity complex, which is a modification that causes the peptide to bind to albumin, a protein that circulates in your blood. Because albumin is not cleared quickly, anything bound to it stays in circulation far longer. The result is a half life of 5.8 to 8.1 days, which is not a modest extension but a fundamentally different pharmacokinetic profile.
What happens at the receptor level during that week of continuous exposure is the important part. Research on GHRH receptor behavior found that continuous stimulation for just four hours reduced GHRH receptor messenger RNA down to 49 to 54 percent of baseline. That is something called receptor downregulation, which means the pituitary's hardware for hearing the GHRH signal degrades under sustained activation. The reduction was dose dependent and driven by the cAMP signaling pathway, meaning it scales with how hard you push it. One week of albumin bound CJC 1295 in your system is not four hours of stimulation, which makes this more than a theoretical concern.
A study specifically on CJC 1295 with DAC found that pulsatile secretion did persist during continuous stimulation, which is the part that gets used to argue DAC is fine. But the full picture matters here. Yes, pulses continued. Pulse frequency and magnitude were preserved. But the trough level, the baseline between pulses, was elevated 7.5 times above normal. So the valleys fill in. Your rhythm no longer looks like a series of distinct peaks with recovery between them. It looks like a flat elevated line with small ripples on top.
That distinction determines your actual outcome.
A human study tested pulsatile versus continuous growth hormone delivery head to head and measured lipolysis, which is the process your fat cells use to break down stored fat and release it as energy. The pulsatile group saw lipolysis nearly double from baseline, going from 4.1 to 7.1. The continuous group ended up at 4.8, which was not statistically different from the baseline of 4.1. Continuous elevation produced essentially no meaningful fat breakdown compared to doing nothing. The pattern of delivery, not the total amount of growth hormone, determined whether the intervention worked at all.
This is where the choice between DAC and no DAC stops being about injection frequency.
If the point of using a GHRH secretagogue is to work with your natural pulsatile rhythm and amplify what your pituitary is already doing, then CJC 1295 without DAC is the version that delivers that. It fits into the rhythm. DAC removes the rhythm.
And if you have already decided that continuous elevation is what you want, then you are not in secretagogue territory anymore. You are in growth hormone territory. Exogenous GH does produce continuous elevation, but it does it with a known dose, a predictable pharmacokinetic profile, and decades of clinical data. CJC 1295 with DAC sits in a middle position where you lose the pulsatile advantage that justified choosing a secretagogue, and you gain neither the precision nor the data set of actual growth hormone therapy.
The reason people use secretagogues instead of growth hormone is to preserve the natural architecture of the system while adding signal to it. DAC does not preserve that architecture. It just does the damage more slowly than a continuous GH infusion would, without the tradeoff of giving you control over exactly how much elevation you are creating.
What you are actually choosing between is a peptide that works with your pituitary and one that runs over it. The injection frequency is the last thing that should make that decision for you.
References
- Surya S et al. The pattern of growth hormone delivery to peripheral tissues determines insulin-like growth factor-1 and lipolytic responses in obese subjects. J Clin Endocrinol Metab. 2009;948:2828-2834 — Pulsatile GH nearly doubled lipolysis 7.1 vs 4.1 baseline, continuous was not significantly different from baseline 4.8 vs 4.1. Source
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295, a long-acting GHRH analog. J Clin Endocrinol Metab. 2006;9112:4792-4797 — CJC-1295 DAC preserved pulse frequency and magnitude but elevated basal trough GH 7.5-fold. Source
- Teichman SL et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;913:799-805 — CJC-1295 DAC half-life 5.8-8.1 days due to albumin binding. Source
- Aleppo G et al. Homologous down-regulation of growth hormone-releasing hormone receptor messenger ribonucleic acid levels. Endocrinology. 1997;1383:1058-1065 — Continuous GHRH exposure for 4 hours reduced GHRH receptor mRNA to 49-54% of baseline, dose-dependent and cAMP-mediated. Source
Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness
If this is the kind of information you want access to on a daily basis, the community is free and there are full courses on training, nutrition, hormones, and supplementation inside. You can ask questions and post your own labs and get feedback from me and from the community.